PDCD1 and melanoma: Blocking of these co-inhibitory molecules by monoclonal antibodies directed against for instance PD-1 and CTLA-4 (known as immune checkpoint inhibitor therapy) has evolved in recent years as a novel and sometimes very effective immunotherapy for cancers like melanoma or lung carcinoma.